Biomea, type 2 diabetes
US FDA lifts clinical hold on Biomea's diabetes trials after safety review
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for type 1 and type 2 diabetes, the drug developer said on Thursday. The regulator had placed a hold on two trials of its lead drug,
FDA lifts hold on diabetes trials after Biomea mitigates liver toxicity risk
Biomea Fusion has escaped from the full clinical hold imposed by the FDA. | Biomea Fusion has escaped from the full clinical hold imposed by the FDA. After reviewing the data, the regulator has cleared Biomea to study its diabetes drug candidate under a revised protocol intended to mitigate liver toxicity concerns.
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug.
US FDA lifts clinical hold on Biomea's diabetes trials
Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its experimental drug for type 1 and 2 diabetes, sending its shares up 6.9%. The decision comes as a boon for the company as the regulator placed a hold on two trials of its lead drug,
Biomea Fusion, Inc.: FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing
bovnews1h
The Biomea Fusion Inc Stock Thriller: Decoding the Mystery Behind BMEA’s Recent Movements
On Thursday, Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $9.57 which represents a slight increase of $0.80 or 9.12% from the prior close of $8.77. The stock opened at $8.98 ...
Biomea Fusion Hold Rating: FDA Clearance and Increased Price Target Amid Cautious Optimism
Barclays analyst Peter Lawson has reiterated their neutral stance on BMEA stock, giving a Hold rating yesterday. Peter Lawson has given his ...
Approvals News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
devdiscourse16h
Current Updates: Major Developments in Health Sector
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
Seeking Alpha9h
BMEA Biomea Fusion, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry
NDAQ:BMEA) Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry ...